- Home
- CANF vs JCTCF Comparison
CANF vs JCTCF Comparison
Compare CANF & JCTCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- JCTCF
- Stock Information
- Founded
- CANF 1994
- JCTCF 1953
- Country
- CANF Israel
- JCTCF United States
- Employees
- CANF N/A
- JCTCF N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- JCTCF RETAIL: Building Materials
- Sector
- CANF Health Care
- JCTCF Consumer Discretionary
- Exchange
- CANF Nasdaq
- JCTCF Nasdaq
- Market Cap
- CANF 14.4M
- JCTCF 14.3M
- IPO Year
- CANF N/A
- JCTCF 1996
- Fundamental
- Price
- CANF $1.97
- JCTCF $4.94
- Analyst Decision
- CANF Strong Buy
- JCTCF
- Analyst Count
- CANF 2
- JCTCF 0
- Target Price
- CANF $14.00
- JCTCF N/A
- AVG Volume (30 Days)
- CANF 115.8K
- JCTCF 7.1K
- Earning Date
- CANF 11-15-2024
- JCTCF 11-26-2024
- Dividend Yield
- CANF N/A
- JCTCF N/A
- EPS Growth
- CANF N/A
- JCTCF N/A
- EPS
- CANF N/A
- JCTCF 0.34
- Revenue
- CANF $667,000.00
- JCTCF $48,553,695.00
- Revenue This Year
- CANF $356.93
- JCTCF N/A
- Revenue Next Year
- CANF N/A
- JCTCF N/A
- P/E Ratio
- CANF N/A
- JCTCF $14.53
- Revenue Growth
- CANF N/A
- JCTCF N/A
- 52 Week Low
- CANF $1.81
- JCTCF $3.86
- 52 Week High
- CANF $4.69
- JCTCF $6.35
- Technical
- Relative Strength Index (RSI)
- CANF 35.55
- JCTCF 62.59
- Support Level
- CANF $1.87
- JCTCF $4.85
- Resistance Level
- CANF $2.04
- JCTCF $4.99
- Average True Range (ATR)
- CANF 0.15
- JCTCF 0.12
- MACD
- CANF 0.00
- JCTCF 0.01
- Stochastic Oscillator
- CANF 18.18
- JCTCF 86.36
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About JCTCF Jewett-Cameron Trading Company
Jewett-Cameron Trading Co Ltd through its subsidiaries engages in the wholesale distribution of a variety of specialty wood products. Its operating segments include, The Industrial wood products segment is engaged in the processing and distribution of industrial wood products. The Pet Fencing and Other segment, which is the key revenue driver, operates as a wholesaler of wood products and a manufacturer and distributor of specialty metal products. The Seed processing and sales segment processes and distributes agricultural seed and Corporate and administrative. The company predominantly operates in United States and also has its presence in Canada, Latin America, Europe and Asia and other regions.